Previous 10 | Next 10 |
Gainers: MYOS RENS Technology (NASDAQ: MYOS ) +210% . More news on: MYOS RENS Technology Inc., Liminal BioSciences Inc., YRC Worldwide Inc., Stocks on the move, , Read more ...
YRC Worldwide (NASDAQ: YRCW ) +123% on receiving $700M CARES act loan from U.S. Treasury. More news on: YRC Worldwide Inc., T2 Biosystems, Inc., Akero Therapeutics, Inc., Stocks on the move, , Read more ...
Alterity Therapeutics (NASDAQ: ATHE ) is up 71% premarket after receiving FDA guidance in relation to the development pathway for ATH434 (previously PBT434), company's lead compound for the treatment of Multiple System Atrophy (MSA), a Parkinsonian disorder. More ne...
MELBOURNE , Australia and SAN FRANCISCO , June 29, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce that it has received guidance from the US Food and Drug Administration (FDA) in relation to the development pat...
MELBOURNE , Austrilia and SAN FRANCISCO , May 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has presented data on ATH434 (formerly PBT434) for the treatment of Multiple System Atrophy at the American Academy of Neurology (AAN) ...
Highlights: European Commission designated Orphan Drug status for ATH434's treatment of Multiple System Atrophy in the European Union Phase 2 preparatory work continues Cash balance of $10.4M MELBOURNE, Australia and SAN FRANCISCO , April 30, 2020 /PRNewswire/ -- Alte...
MELBOURNE , Australia and SAN FRANCISCO , Feb. 7, 2020 /PRNewswire/ -- Alterity Therapeutics Limited (ASX:ATH, NASDAQ:ATHE) has received notification from the Listing Qualifications Department of NASDAQ advising the Company that it is currently non-compliant with NASDAQ's requi...
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that it has successfully completed its Phase 1 study of PBT434, a novel, orally bioavailable small molecule inhibitor of alpha- synuclein aggregation. Alpha-syn...
The following slide deck was published by Alterity Therapeutics Limited in conjunction with this Read more ...
Aquantia (NYSE: AQ ) +36% on $452M sale to Marvell. More news on: Aquantia Corp., Ovid Therapeutics Inc., Adaptimmune Therapeutics plc, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Alterity Therapeutics Limited Company Name:
ATHE Stock Symbol:
NYSE Market:
Alterity Therapeutics Limited Website:
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings ...
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings ...
MELBOURNE, Australia and SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today an...